Join
Live feed
·
PRReleasevia Quantisnow
Ocugen Inc. logo

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

ByQuantisnow·Wall Street's wire, on your screen.
OCGN· Ocugen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCGN (Ocugen Inc.) and more on Quantisnow.